MONDAY, June 8, 2026 (HealthDay News) -- Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with reduced risks for thromboembolic events, emergency department use, and mortality among adults with obesity and autoimmune diseases (AIDs), according to a study published online June 6 in the Journal of the American Heart Association to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans.Hao Dai, Ph.D., from the Indiana University School of Medicine in Indianapolis, and colleagues conducted a retrospective cohort study, which emulated a target trial using 2014 to 2024 electronic health record data to examine the association between GLP-1 RA use and major adverse cardiovascular and thromboembolic event risk among adults with obesity and AID
An increase in lipopolysaccharide (LPS) after eating has also been found to help to improve postprandial hyperglycemia 15
The peptide is an NNMT (Nicotinamide N-methyltransferase) inhibitor
SD prepared and wrote the original draft and was responsible for visualization
Also, they stimulate the endothelium to produce nitric oxide, reduce oxidative stress, and have antiatherogenic and anti-inflammatory effects
